These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

771 related articles for article (PubMed ID: 24419085)

  • 1. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
    Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
    Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.
    Fabian J; Opitz D; Althoff K; Lodrini M; Hero B; Volland R; Beckers A; de Preter K; Decock A; Patil N; Abba M; Kopp-Schneider A; Astrahantseff K; Wünschel J; Pfeil S; Ercu M; Künkele A; Hu J; Thole T; Schweizer L; Mechtersheimer G; Carter D; Cheung BB; Popanda O; von Deimling A; Koster J; Versteeg R; Schwab M; Marshall GM; Speleman F; Erb U; Zoeller M; Allgayer H; Simon T; Fischer M; Kulozik AE; Eggert A; Witt O; Schulte JH; Deubzer HE
    Oncotarget; 2016 Oct; 7(41):66344-66359. PubMed ID: 27572323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells.
    Cortés C; Kozma SC; Tauler A; Ambrosio S
    Cell Oncol (Dordr); 2015 Oct; 38(5):341-52. PubMed ID: 26306783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
    Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX
    Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma.
    Ochiai H; Takenobu H; Nakagawa A; Yamaguchi Y; Kimura M; Ohira M; Okimoto Y; Fujimura Y; Koseki H; Kohno Y; Nakagawara A; Kamijo T
    Oncogene; 2010 May; 29(18):2681-90. PubMed ID: 20190806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
    Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F
    Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
    Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH
    Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.
    Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG
    FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas.
    Kaneko Y; Suenaga Y; Islam SM; Matsumoto D; Nakamura Y; Ohira M; Yokoi S; Nakagawara A
    Cancer Sci; 2015 Jul; 106(7):840-7. PubMed ID: 25880909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model.
    Waldeck K; Cullinane C; Ardley K; Shortt J; Martin B; Tothill RW; Li J; Johnstone RW; McArthur GA; Hicks RJ; Wood PJ
    Int J Cancer; 2016 Jul; 139(1):194-204. PubMed ID: 26914605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma.
    Lodrini M; Oehme I; Schroeder C; Milde T; Schier MC; Kopp-Schneider A; Schulte JH; Fischer M; De Preter K; Pattyn F; Castoldi M; Muckenthaler MU; Kulozik AE; Westermann F; Witt O; Deubzer HE
    Nucleic Acids Res; 2013 Jul; 41(12):6018-33. PubMed ID: 23625969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NLRR1 enhances EGF-mediated MYCN induction in neuroblastoma and accelerates tumor growth in vivo.
    Hossain S; Takatori A; Nakamura Y; Suenaga Y; Kamijo T; Nakagawara A
    Cancer Res; 2012 Sep; 72(17):4587-96. PubMed ID: 22815527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
    Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
    Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.
    Song L; Ara T; Wu HW; Woo CW; Reynolds CP; Seeger RC; DeClerck YA; Thiele CJ; Sposto R; Metelitsa LS
    J Clin Invest; 2007 Sep; 117(9):2702-12. PubMed ID: 17710228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma.
    Haug BH; Henriksen JR; Buechner J; Geerts D; Tømte E; Kogner P; Martinsson T; Flægstad T; Sveinbjørnsson B; Einvik C
    Carcinogenesis; 2011 Jul; 32(7):1005-12. PubMed ID: 21572098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2.
    Ding Y; Yang J; Ma Y; Yao T; Chen X; Ge S; Wang L; Fan X
    J Exp Clin Cancer Res; 2019 Dec; 38(1):498. PubMed ID: 31856871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications.
    Corvetta D; Chayka O; Gherardi S; D'Acunto CW; Cantilena S; Valli E; Piotrowska I; Perini G; Sala A
    J Biol Chem; 2013 Mar; 288(12):8332-8341. PubMed ID: 23362253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
    Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
    PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.